SPG20 Antibody

What are the optimal applications for SPG20 antibody detection in cellular systems?

SPG20 antibodies have been validated across multiple experimental platforms with specific recommended dilutions for each application. The most reliable detection methods include Western Blotting, Immunohistochemistry, Immunofluorescence, Flow Cytometry, and Immunoprecipitation, with each requiring specific optimization parameters.

Based on consolidated validation data from multiple sources, the following application-specific dilutions are recommended :

For optimal results, researchers should test a range of dilutions within these parameters and incorporate appropriate positive and negative controls specific to their experimental systems .

How should SPG20 antibodies be stored and handled to maintain reactivity?

Proper storage and handling of SPG20 antibodies is critical for maintaining immunoreactivity. Most commercially available SPG20 antibodies are formulated in PBS with stabilizing agents such as glycerol (50%) and preservatives like sodium azide (0.02%) .

Storage recommendations based on consolidated literature:

• Store at -20°C to maintain stability for up to 12 months

• Avoid repeated freeze-thaw cycles as this significantly reduces antibody functionality

• For conjugated antibodies (e.g., CoraLite® 488-labeled), protect from light exposure during storage

• Aliquoting is recommended for antibodies that will be accessed frequently, though some formulations specify this is unnecessary for -20°C storage

For working solutions, maintain at 4°C for up to two weeks. Return to -20°C for longer-term storage between experiments to preserve reactivity .

What cross-reactivity should researchers expect when using SPG20 antibodies across species?

SPG20 antibodies show varying degrees of cross-reactivity across mammalian species, with most commercial antibodies demonstrating validated reactivity against human, mouse, and rat SPG20 protein . This cross-reactivity is supported by the high sequence homology between these species - mouse SPG20 shows approximately 84% sequence identity to human SPG20, while rat exhibits approximately 81% sequence identity .

For research involving other species, targeted validation is strongly recommended before proceeding with full experimental protocols. Several antibodies have predicted cross-reactivity with additional species including cow, dog, guinea pig, horse, rabbit, and zebrafish based on sequence homology, but these require empirical verification .

When selecting an antibody for cross-species applications, prioritize those targeting highly conserved epitopes. For example, antibodies targeting the N-terminal region (AA 1-350) of SPG20 have demonstrated broader cross-reactivity than those targeting species-variable regions .

How can researchers effectively validate SPG20 antibody specificity for studies investigating Troyer syndrome mutations?

Validating SPG20 antibody specificity is particularly critical when investigating Troyer syndrome, where SPG20 mutations result in loss of protein expression. A systematic validation approach should include multiple complementary methods:

• Genetic validation controls: Include cell lines derived from Troyer syndrome patients (with confirmed SPG20 mutations) as negative controls in Western blot analyses. These samples should show absence of the SPG20 band at the expected molecular weight (75-84 kDa) .

• Knockdown/knockout validation: Use siRNA, shRNA, or CRISPR-Cas9 to generate SPG20 knockdown/knockout cell lines. This approach has been validated in at least three published studies using commercially available antibodies . Compare expression between wildtype and knockdown/knockout samples using quantitative Western blotting.

• Recombinant protein overexpression: Transfect cells with tagged SPG20 constructs (such as HA-SPG20, YFP-SPG20, or Che-SPG20) and confirm detection with both tag-specific antibodies and SPG20 antibodies .

• RNA expression correlation: Perform quantitative PCR for SPG20 mRNA levels and correlate with protein detection using the antibody to ensure concordance across samples .

A comprehensive validation should demonstrate specificity using at least two independent methods before proceeding with experimental studies of Troyer syndrome pathophysiology .

What protocols are most effective for detecting SPG20 localization to lipid droplets in cellular systems?

SPG20/Spartin has been established to localize to lipid droplets under specific cellular conditions. Optimized protocols for visualizing this association require careful experimental design :

Recommended immunofluorescence protocol for lipid droplet colocalization:

• Cell preparation: Culture cells (HeLa cells show robust SPG20-lipid droplet association) on coverslips. To enhance lipid droplet formation, supplement media with oleic acid (OA) at 500 μM for 12-24 hours .

• Fixation and permeabilization: Fix cells with 4% paraformaldehyde for 15 minutes. Permeabilize using a gentle detergent (0.1% Triton X-100) to preserve lipid droplet morphology .

• Antibody staining: Apply SPG20 antibody at a 1:50-1:100 dilution (for immunofluorescence applications). For dual visualization, include lipid droplet-specific stains such as BODIPY 493/503 (1 μg/ml) .

• Imaging considerations: Use confocal microscopy with optical sectioning to accurately determine co-localization. Employ super-resolution techniques if available for more detailed spatial analysis .

Importantly, SPG20 localization to lipid droplets is enhanced following oleic acid treatment, with HA-SPG20 showing diffuse cytoplasmic staining under basal conditions but prominent lipid droplet localization after oleic acid supplementation . This dynamic localization pattern should be considered when designing experiments to study SPG20's role in lipid metabolism.

How can researchers optimize SPG20 antibodies for studying mitochondrial calcium homeostasis in Troyer syndrome models?

Recent research has implicated SPG20 in mitochondrial calcium homeostasis, which may contribute to Troyer syndrome pathophysiology . When investigating this pathway, consider these specialized protocols:

• Co-immunostaining optimization: For detecting SPG20 alongside mitochondrial markers, use sequential immunostaining with the following validated antibody combinations:

  • Anti-SPG20 (1:100 dilution) paired with mouse monoclonal anti-TOM20 (mitochondrial outer membrane marker)

  • Anti-SPG20 paired with mouse monoclonal anti-OPA1 (inner mitochondrial membrane marker)

• Live-cell calcium imaging integration: For functional studies, combine immunofluorescence with calcium imaging:

  • Treat cells with mitochondrial disruptors (e.g., FCCP) to assess calcium handling

  • Compare calcium responses between SPG20-positive and SPG20-deficient cells

  • Correlate calcium signals with SPG20 localization using post-imaging fixation and immunostaining

• Subcellular fractionation validation: When isolating mitochondria for biochemical analyses:

  • Validate mitochondrial fractions using established markers (TOM20, OPA1)

  • Use proteinase K protection assays to determine if SPG20 is protected within mitochondria or associated with the outer membrane

  • Compare results between native detection methods and epitope-tagged SPG20 constructs

This integrated approach allows correlation between SPG20 localization, expression levels, and functional consequences for mitochondrial calcium homeostasis in the context of Troyer syndrome pathophysiology .

What control systems should be implemented when using SPG20 antibodies for cancer biomarker research?

When investigating SPG20 as a potential cancer biomarker, particularly in colorectal cancer where SPG20 promoter hypermethylation has been documented , the following control systems are essential:

• Methylation-expression correlation controls:

  • Include matched tumor/normal tissue pairs to assess SPG20 protein expression relative to promoter methylation status

  • Use cell lines with known SPG20 methylation profiles as reference standards

  • Compare SPG20 protein detection with quantitative methylation-specific PCR data

• Tissue-specific expression controls:

  • For immunohistochemical applications, include multiple tissue types with validated SPG20 expression patterns

  • Normal liver, brain, and adipose tissue samples serve as reliable positive controls for SPG20 detection

  • Include serial sections stained with isotype control antibodies at matching concentrations

• Validation across detection platforms:

  • Confirm IHC findings with quantitative Western blot analyses when possible

  • For stronger biomarker validation, correlate protein detection with mRNA expression data

  • Document band patterns across various cancer and normal cell lines to establish expression profiles

When reporting SPG20 expression patterns in cancer tissues, researchers should specify antigen retrieval methods, as different protocols may yield varying results. Notably, TE buffer (pH 9.0) is recommended for optimal SPG20 detection in FFPE tissues, although citrate buffer (pH 6.0) may be used as an alternative .

How should researchers address molecular weight variations when detecting SPG20 protein?

SPG20 detection often reveals molecular weight variations that can complicate data interpretation. Based on consolidated literature, researchers should anticipate the following:

• Expected molecular weight patterns:

  • Calculated molecular weight: 75 kDa and 85 kDa (theoretical)

  • Observed molecular weight: 75-84 kDa range in most human cell lines

  • Lower molecular weight bands may appear in certain tissue types or experimental conditions

• Addressing molecular weight discrepancies:

  • Run longer SDS-PAGE separations (10-12% gels) for better resolution in the 70-90 kDa range

  • Include positive control lysates from HEK-293 or HeLa cells, which consistently show clear SPG20 bands

  • For novel cell lines or tissues, validate bands by comparing with SPG20 knockdown/overexpression controls

• Distinguishing post-translational modifications:

  • SPG20 undergoes ubiquitination via interaction with HECT ubiquitin ligases through its PPxY motif

  • Higher molecular weight bands (>90 kDa) may represent ubiquitinated forms

  • Treatment with deubiquitinating enzymes prior to Western blotting can help identify modified forms

When reporting molecular weight variations, clearly document the electrophoresis conditions, including gel percentage, running buffer composition, and molecular weight standards used .

What methodological approaches should be used when studying SPG20's interaction with ubiquitin ligases?

SPG20 interacts with several HECT ubiquitin ligases through its PPxY motif, a critical interaction for understanding its cellular functions. When studying these interactions, implement these methodological approaches:

• Co-immunoprecipitation optimization:

  • Use mild lysis conditions (e.g., 1% NP-40 or 0.5% Triton X-100) to preserve protein-protein interactions

  • SPG20 antibodies have been validated for immunoprecipitation at 0.5-4.0 μg per 1.0-3.0 mg of total protein lysate

  • Include both N-terminal and C-terminal tagged SPG20 constructs to confirm that tag position doesn't interfere with ubiquitin ligase binding

  • Validated interacting partners include WWP1, WWP2, Itch, Smurf1, and Smurf2 ubiquitin ligases

• Domain mapping experiments:

  • The PPxY motif in SPG20 is essential for ubiquitin ligase binding; SPG20dPY mutants serve as negative controls

  • The central WW domains of ubiquitin ligases (e.g., WWP1) are necessary and sufficient for SPG20 interaction

  • Yeast two-hybrid assays have validated these domain-specific interactions and can be used as complementary approaches

• Functional validation of interactions:

  • Overexpression of SPG20 can block YFP-WWP1 recruitment to MLV Gag-CFP puncta, providing a functional readout of competitive binding

  • MLV virus-like particle release assays can serve as functional indicators of SPG20-ubiquitin ligase interactions

These methodological approaches provide multiple layers of validation for studying SPG20's interactions with ubiquitin ligases, enabling researchers to confidently assess both binding requirements and functional consequences .

What spatial and temporal expression patterns should researchers expect when examining SPG20 during development?

SPG20's developmental expression patterns are critical for understanding its role in Troyer syndrome, which includes both developmental and degenerative features. Based on human and mouse studies, researchers should expect these distinct patterns :

• Spatial expression during development:

  • Embryonic expression: Robust and specific expression in the limb buds, face, and forebrain during early morphogenesis

  • Fetal expression: Notable expression in lens placode, pigment epithelium, cochlear epithelium, and condensing mesenchyme at sites of myogenic or cartilage formation

  • Brain development: Low relative expression throughout the developing brain with no apparent regional distinctions at E12.5 and E14.5

• Adult neuroanatomical expression patterns:

  • Hippocampus: Elevated expression throughout hippocampal stratum pyramidale of CA fields and dentate gyrus

  • Cerebral cortex: Low expression with no apparent laminar or cell class specificity

  • Cerebellum: Expression in Purkinje cells, granule cells, and scattered cells in the molecular layer

  • Brainstem: Robust expression in large neurons (likely motor neurons) and in the facial nucleus

  • Spinal cord: Expression in cells distributed throughout with no noticeable discontinuities

• Quantitative temporal profiling:

  • Highest expression occurs during embryonic stages, particularly during limb and facial development

  • Expression decreases during late fetal development and remains relatively low but stable throughout adulthood

When studying developmental expression patterns, researchers should optimize antibody dilutions specifically for embryonic tissues, as the high expression levels during development may require more dilute antibody concentrations than typically used for adult tissues .

How can researchers effectively use SPG20 antibodies in neurodegenerative disease models?

SPG20 mutations cause Troyer syndrome, making SPG20 antibodies valuable tools for studying hereditary spastic paraplegias and related neurodegenerative conditions. Implementation of these specialized approaches is recommended:

• Mouse model validation strategies:

  • Compare SPG20 detection between wildtype mice and those carrying Spg20 mutations or deletions

  • Validate antibody reactivity in mouse tissue using the established cross-reactivity of commercial antibodies with mouse SPG20 (approximately 84% sequence identity to human)

  • For developmental studies, examine expression in embryonic limb buds, face, and forebrain, where SPG20 is robustly expressed

• Neuron-specific detection optimization:

  • For immunohistochemistry in neural tissues, optimize antigen retrieval using TE buffer (pH 9.0)

  • In spinal cord sections, robust SPG20 expression should be detectable with antibody dilutions of 1:20-1:200

  • Double-labeling with motor neuron markers is recommended, as SPG20 is particularly expressed in large brainstem neurons

• Patient-derived cellular models:

  • When working with patient-derived cells (lymphoblasts or fibroblasts), SPG20 antibodies can confirm protein absence in Troyer syndrome patients

  • For induced pluripotent stem cell (iPSC) models, track SPG20 expression through the neuronal differentiation process

  • Compare expression patterns between control and patient-derived neurons, with particular attention to motor neuron lineages

These approaches leverage SPG20 antibodies to advance understanding of pathogenic mechanisms in hereditary spastic paraplegias and may reveal therapeutic targets for these currently untreatable conditions .

What technical considerations are important when using SPG20 antibodies for flow cytometry applications?

Flow cytometry applications with SPG20 antibodies require specific technical considerations to generate reliable data, particularly for intracellular staining:

• Optimized intracellular staining protocol:

  • Fixation: Use 4% paraformaldehyde for 10-15 minutes at room temperature

  • Permeabilization: Apply 0.1-0.3% saponin or 0.1% Triton X-100 in PBS with 3% BSA

  • Blocking: Include 3-5% BSA and 5-10% normal serum from the secondary antibody species

  • Primary antibody: Use SPG20 antibody at 0.20-0.40 μg per 10^6 cells in 100 μl suspension

  • Secondary antibody: Apply fluorophore-conjugated secondary at manufacturer-recommended dilutions

• Validated positive control systems:

  • HepG2 cells have been validated for flow cytometry with SPG20 antibodies

  • For comparison across cell types, establish baseline staining intensity in HepG2 cells

  • Include isotype control antibodies at matching concentrations

• Direct conjugate considerations:

  • CoraLite® Plus 488-conjugated SPG20 antibodies eliminate secondary antibody requirements

  • These conjugates have excitation/emission maxima of 493/522 nm

  • When using direct conjugates, titrate across a range of concentrations (recommended 0.40 μg per 10^6 cells)

  • Protect samples from light exposure during staining, washing, and analysis

• Data analysis recommendations:

  • Gate on viable cells using appropriate viability dyes

  • For heterogeneous populations, use lineage markers to identify specific cell types

  • Quantify data as median fluorescence intensity rather than percent positive cells

  • Compare relative expression levels across experimental conditions rather than absolute values

These technical considerations ensure optimal detection of SPG20 in flow cytometry applications, enabling quantitative analysis of expression across various experimental conditions .

How can researchers utilize SPG20 antibodies to investigate its role in lipid metabolism disorders?

SPG20's association with lipid droplets suggests potential roles in lipid metabolism disorders. When investigating these connections, researchers should implement these specialized approaches:

• Lipid droplet dynamics assessment:

  • Use SPG20 antibodies in combination with lipid droplet stains (BODIPY 493/503) to visualize colocalization

  • Quantify lipid droplet size and number in relation to SPG20 expression levels

  • Compare wildtype cells with SPG20 knockdown/knockout models to assess effects on lipid droplet turnover

• Metabolic challenge protocols:

  • Supplement culture media with oleic acid (500 μM) to enhance lipid droplet formation and SPG20 localization

  • Monitor dynamic translocation of SPG20 to lipid droplets following oleic acid treatment using time-course immunofluorescence

  • Combine with lipidomic analyses to correlate SPG20 expression with specific lipid profiles

• Tissue-specific expression analysis:

  • Examine SPG20 expression in metabolically active tissues such as liver, adipose tissue, and muscle

  • Compare expression patterns in normal versus metabolically challenged states (e.g., high-fat diet models)

  • Correlate SPG20 localization with markers of metabolic stress or inflammation

These approaches leverage SPG20 antibodies to investigate its potential roles in lipid metabolism disorders, which may reveal connections between hereditary spastic paraplegias and metabolic dysfunction .

What protocols are recommended for studying SPG20's involvement in cancer progression beyond promoter methylation?

While SPG20 promoter hypermethylation has been documented in colorectal cancer, its broader roles in cancer biology warrant investigation using these recommended protocols:

• Cytokinesis assessment in cancer models:

  • Examine SPG20 expression in relation to cytokinesis completion in cancer cell lines

  • Use time-lapse microscopy with immunofluorescence to correlate SPG20 expression with successful cell division

  • Compare cytokinesis outcomes between cells with varying SPG20 expression levels

• Metastatic potential correlation studies:

  • Analyze SPG20 expression across primary tumors and matched metastatic lesions

  • Implement tissue microarray approaches with SPG20 immunohistochemistry (antibody dilution 1:400-1:1600)

  • Correlate expression patterns with established markers of metastatic potential

• Cancer stem cell characterization:

  • Examine SPG20 expression in purified cancer stem cell populations

  • Use flow cytometry with SPG20 antibodies (0.20-0.40 μg per 10^6 cells) combined with established cancer stem cell markers

  • Assess whether SPG20 expression correlates with stem-like properties or differentiation status

• Therapeutic response prediction:

  • Monitor SPG20 expression before and after treatment with chemotherapeutic agents

  • Correlate expression patterns with treatment sensitivity or resistance

  • Investigate whether manipulating SPG20 levels alters treatment responses

These protocols extend SPG20 research beyond promoter methylation studies, potentially revealing broader roles in cancer biology that could inform biomarker development and therapeutic strategies .